Non-conventional compounds with potential therapeutic effects against Alzheimer’s disease

References

• Appleby BS, Nacopoulos D, Milano N, et al. A review: treatment of Alzheimer’s disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35:1–22.
   PubMed Web of Science ®Google Scholar
• Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov. 2012;11:833–846.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006395.
   PubMed Web of Science ®Google Scholar
• Bachurin SO, Bovina EV, Ustyugov AA. Drugs in clinical trials for Alzheimer’s disease: the major trends. Med Res Rev. 2017;37:1186–1225.
   PubMed Web of Science ®Google Scholar
• Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with lewy bodies. Expert Opin Pharmacother. 2014;15:1797–1810.
   PubMed Web of Science ®Google Scholar
• Araki W. Potential repurposing of oncology drugs for the treatment of Alzheimer’s disease. BMC Med England. 2013;11:82.
   PubMed Web of Science ®Google Scholar
• Hayes CD, Dey D, Palavicini JP, et al. Striking reduction of amyloid plaque burden in an Alzheimer’s mouse model after chronic administration of carmustine. BMC Med. 2013;11:81.
   PubMed Web of Science ®Google Scholar
• Choi Y, Jeong HJ, Liu QF, et al. Clozapine improves memory impairment and reduces abeta level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer’s disease. Mol Neurobiol. 2017;54:450–460.
   PubMed Web of Science ®Google Scholar
• Kukharsky MS, Ovchinnikov RK, Bachurin SO. [Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer’s disease]. Zhurnal Nevrol i psikhiatrii Im SS Korsakova. 2015;115:103–114.
   Google Scholar
• Nussbaum JM, Seward ME, Bloom GS. Alzheimer disease: a tale of two prions. Prion. 2013;7:14–19.
   PubMed Web of Science ®Google Scholar
• Carreiras MC, Mendes E, Perry MJ, et al. The multifactorial nature of Alzheimer’s disease for developing potential therapeutics. Curr Top Med Chem. 2013;13:1745–1770.
   PubMed Web of Science ®Google Scholar
• De-Paula VJ, Radanovic M, Diniz BS, et al. Alzheimer’s disease. Subcell Biochem. 2012;65:329–352.
   PubMedGoogle Scholar
• Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell. 2010;142:387–397.
   PubMed Web of Science ®Google Scholar
• Ballard C, Corbett A, Sharp S. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease. Expert Rev Neurother Internet. 2011;11:327–329.
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
   PubMed Web of Science ®Google Scholar
• Zhang B, Gaiteri C, Bodea L-G, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell. 2013;153:707–720.
   PubMed Web of Science ®Google Scholar
• Shi X-W, Liu L, Gao J-M, et al. Cyathane diterpenes from Chinese mushroom sarcodon scabrosus and their neurite outgrowth-promoting activity. Eur J Med Chem. 2011;46:3112–3117.
   PubMed Web of Science ®Google Scholar
• Zhang -C-C, Cao C-Y, Kubo M, et al. Chemical constituents from hericium erinaceus promote neuronal survival and potentiate neurite outgrowth via the TrkA/Erk1/2 pathway. Int J Mol Sci. 2017;18:1659.
   Web of Science ®Google Scholar
• Cao C-Y, Zhang -C-C, Shi X-W, et al. Sarcodonin G derivatives exhibit distinctive effects on neurite outgrowth by modulating NGF signaling in PC12 cells. ACS Chem Neurosci. 2018;9:1607–1615.
   PubMed Web of Science ®Google Scholar
• Tang D, Liu -L-L, He Q-R, et al. Ansamycins with antiproliferative and antineuroinflammatory activity from moss-soil-derived Streptomyces cacaoi subsp. asoensis H2S5. J Nat Prod. 2018;81:1984–1991.
   PubMed Web of Science ®Google Scholar
• Kou R-W, Du S-T, Li Y-X, et al. Cyathane diterpenoids and drimane sesquiterpenoids with neurotrophic activity from cultures of the fungus cyathus africanus. J Antibiot. 2019;72:15–21.
   PubMed Web of Science ®Google Scholar
• Bai R, Zhang -C-C, Yin X, et al. Striatoids A-F, Cyathane diterpenoids with neurotrophic activity from cultures of the fungus cyathus striatus. J Nat Prod. 2015;78:783–788.
   PubMed Web of Science ®Google Scholar
• Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698–712.
   PubMed Web of Science ®Google Scholar
• Corbett A, Ballard C. Is a potential Alzheimer’s therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms? Expert Opin Investig Drugs Internet. 2013;22:941–943.
   PubMed Web of Science ®Google Scholar
• Lourenco MV, Frozza RL, de Freitas GB, et al. Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models. Nat Med Available from. 2019;25:165–175.
   PubMed Web of Science ®Google Scholar
• Kumar K, Kumar A, Keegan RM, et al. Recent advances in the neurobiology and neuropharmacology of Alzheimer’s disease. Biomed Pharmacother. 2018;98:297–307.
   PubMed Web of Science ®Google Scholar
• Jones EL, Hanney M, Francis PT, et al. Amyloid beta concentrations in older people with down syndrome and dementia. Neurosci Lett. 2009;451:162–164.
   PubMed Web of Science ®Google Scholar
• Saez-Orellana F, Godoy PA, Bastidas CY, et al. ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of beta-amyloid peptide in hippocampal neurons. Neuropharmacology. 2016;100:116–123.
   PubMed Web of Science ®Google Scholar
• Godyn J, Jonczyk J, Panek D, et al. Therapeutic strategies for Alzheimer’s disease in clinical trials. Pharmacol Rep. 2016;68:127–138.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
   PubMed Web of Science ®Google Scholar
• Golde TE. The pathogenesis of Alzheimer’s disease and the role of Abeta42. CNS Spectr. 2007;12:4–6.
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med Internet. 2012;367:795–804.
   PubMed Web of Science ®Google Scholar
• Schenk D, Basi GS, Pangalos MN. Treatment strategies targeting amyloid beta-protein. Cold Spring Harb Perspect Med. 2012;2:a006387.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Ma B, McElheny D, et al. Abeta(1–42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer’s disease. Nat Struct Mol Biol. 2015;22:499–505.
   PubMed Web of Science ®Google Scholar
• Almond MH, Edwards MR, Barclay WS, et al. Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax. 2013;68:684–686.
   PubMed Web of Science ®Google Scholar
• Chidiac C. Pneumococcal infections and adult with risk factors. Med Mal Infect. 2012;42:517–524.
   PubMed Web of Science ®Google Scholar
• Bastard J-P, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Gustafson DR, Barrett-Connor E, et al. Central obesity and increased risk of dementia more than three decades later. Neurology. 2008;71:1057–1064.
   PubMed Web of Science ®Google Scholar
• Brown BM, Peiffer JJ, Martins RN. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer’s disease?. Mol Psychiatry. 2013;18:864–874.
   PubMed Web of Science ®Google Scholar
• Tajiri N, Kellogg SL, Shimizu T, et al. Traumatic brain injury precipitates cognitive impairment and extracellular abeta aggregation in Alzheimer’s disease transgenic mice. PLoS One. 2013;8:e78851.
   PubMed Web of Science ®Google Scholar
• Ramlackhansingh AF, Brooks DJ, Greenwood RJ, et al. Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 2011;70:374–383.
   PubMed Web of Science ®Google Scholar
• Sastre M, Dewachter I, Landreth GE, et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immuno stimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci. 2003;23:9796–9804.
   PubMed Web of Science ®Google Scholar
• Shi H, Belbin O, Medway C, et al. Genetic variants influencing human aging from late-onset Alzheimer’s disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging Internet. 2012;33:1849.e5–1849.18. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4120742/
   Web of Science ®Google Scholar
• Czirr E, Wyss-Coray T. The immunology of neurodegeneration. J Clin Invest. 2012;122:1156–1163.
   PubMed Web of Science ®Google Scholar
• Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology Internet. 2012;79:897–905. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425844/
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med Internet. 2007;13:1359.
   PubMed Web of Science ®Google Scholar
• Britschgi M, Rufibach K, Huang SLB, et al. Modeling of pathological traits in Alzheimer’s disease based on systemic extracellular signaling proteome. Mol Cell Proteomics. 2011;10:M111.008862.
   PubMed Web of Science ®Google Scholar
• Johnstone D, Milward EA, Berretta R, et al. Multivariate protein signatures of pre-clinical Alzheimer’s disease in the Alzheimer’s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One. 2012;7:e34341.
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009;110:1129–1134.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–185.
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890.
   PubMed Web of Science ®Google Scholar
• Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283:29615–29619.
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci. 2007;8:499–509.
   PubMed Web of Science ®Google Scholar
• Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352–357.
   PubMed Web of Science ®Google Scholar
• Cheng IH, Scearce-Levie K, Legleiter J, et al. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818–23828.
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat Neurosci Internet. 2004;8(79). DOI:10.1038/nn1372
   PubMedGoogle Scholar
• Head E, Pop V, Vasilevko V, et al. A two-year study with fibrillar β-Amyloid (Aβ) immunization in aged canines: effects on cognitive function and brain Aβ. J Neurosci Internet. 2008;28:3555LP–3566. Available from: http://www.jneurosci.org/content/28/14/3555.abstract
   Web of Science ®Google Scholar
• Yan P, Bero AW, Cirrito JR, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706–10714.
   PubMed Web of Science ®Google Scholar
• Willem M, Garratt AN, Novak B, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664–666.
   PubMed Web of Science ®Google Scholar
• Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014;13:319–329.
   PubMed Web of Science ®Google Scholar
• Kuhn P-H, Koroniak K, Hogl S, et al. Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. Embo J Internet. 2012;31:3157–3168. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400020/
   PubMed Web of Science ®Google Scholar
• Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease. Alzheimers Res Ther Internet. 2014;6:89. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304279/
   PubMed Web of Science ®Google Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature Internet. 2012;488:96.
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.
   PubMed Web of Science ®Google Scholar
• Nisbet RM, Polanco J-C, Ittner LM, et al. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol. 2015;129:207–220.
   PubMed Web of Science ®Google Scholar
• Tomita T. Secretase inhibitors and modulators for Alzheimer’s disease treatment. Expert Rev Neurother. 2009;9:661–679.
   PubMed Web of Science ®Google Scholar
• Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci. 1991;12:383–388.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. Resolving controversies on the path to Alzheimer’s therapeutics. Nat Med. 2011;17:1060–1065.
   PubMed Web of Science ®Google Scholar
• Khan A, Corbett A, Ballard C. Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets. Expert Rev Neurother. 2017;17:683–695.
   PubMed Web of Science ®Google Scholar
• Cole SL, Vassar R. The role of amyloid precursor protein processing by BACE1, the β-Secretase, in Alzheimer disease pathophysiology. J Biol Chem Internet. 2008;283:29621–29625. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662048/
   PubMed Web of Science ®Google Scholar
• Chauhan V, Chauhan A. Oxidative stress in Alzheimer’s disease. Pathophysiol Off J Int Soc Pathophysiol. 2006;13:195–208.
   PubMedGoogle Scholar
• Huang W-J, Zhang X, Chen -W-W. Role of oxidative stress in Alzheimer’s disease. Biomed Reports. 2016;4:519–522.
   PubMed Web of Science ®Google Scholar
• Kumar S, Chowdhury S, Kumar S. In silico repurposing of antipsychotic drugs for Alzheimer’s disease. BMC Neurosci. 2017;18:76.
   PubMed Web of Science ®Google Scholar
• Son S-Y, Ma J, Kondou Y, et al. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc Natl Acad Sci U S A. 2008;105:5739–5744.
   PubMed Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50:5848–5852.
   PubMed Web of Science ®Google Scholar
• Veitinger M, Varga B, Guterres SB, et al. Platelets, a reliable source for peripheral Alzheimer’s disease biomarkers?. Acta Neuropathol Commun. 2014;2:65.
   PubMed Web of Science ®Google Scholar
• Finberg JPM, Rabey JM. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front Pharmacol. 2016;7:340.
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG. Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine–searching for the connections. Br J Pharmacol. 2012;167:324–352.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer’s disease: therapeutic implications. CNS Drugs. 2003;17:641–652.
   PubMed Web of Science ®Google Scholar
• Mitra A. Therapeutic interventions in Alzheimer disease.Kishore U, editor. Rijeka: InTech; 2013. Ch. 12.: DOI:10.5772/54915
   Google Scholar
• Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res. 2013;24:358–369.
   PubMed Web of Science ®Google Scholar
• Garcia ML, Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol. 2001;13:41–48.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Harrington CR, Storey JMD. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol. 2014;88:529–539.
   PubMed Web of Science ®Google Scholar
• Lee VM-Y, Trojanowski JQ. The disordered neuronal cytoskeleton in Alzheimer’s disease. Curr Opin Neurobiol Internet. 1992;2:653–656. Available from: http://www.sciencedirect.com/science/article/pii/095943889290034I
   PubMed Web of Science ®Google Scholar
• Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003;60:1696–1702.
   PubMed Web of Science ®Google Scholar
• Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–639.
   PubMed Web of Science ®Google Scholar
• Steinhilb ML, Dias-Santagata D, Fulga TA, et al. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell. 2007;18:5060–5068.
   PubMed Web of Science ®Google Scholar
• Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics Internet. 2008;5:443–457. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084246/
   PubMed Web of Science ®Google Scholar
• Illenberger S, Zheng-Fischhofer Q, Preuss U, et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease. Mol Biol Cell. 1998;9:1495–1512.
   PubMed Web of Science ®Google Scholar
• Gong C-X, Liu F, Grundke-Iqbal I, et al. Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm. 2005;112:813–838.
   PubMed Web of Science ®Google Scholar
• Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer’s disease. Expert Rev Neurother. 2010;10:711–728.
   PubMed Web of Science ®Google Scholar
• Iqbal K, Liu F, Gong C-X. Tau and neurodegenerative disease: the story so far. Nat Rev Neurol. 2016;12:15–27.
   PubMed Web of Science ®Google Scholar
• Wu X-L, Pina-Crespo J, Zhang Y-W, et al. Tau-mediated neurodegeneration and potential implications in diagnosis and treatment of Alzheimer’s disease. Chin Med J (Engl). 2017;130:2978–2990.
   PubMed Web of Science ®Google Scholar
• Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018;14:399–415.
   PubMed Web of Science ®Google Scholar
• Ando K, Kabova A, Stygelbout V, et al. Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study. J Alzheimers Dis. 2014;40(Suppl 1):S135–45.
   PubMedGoogle Scholar
• Bi M, Ittner A, Ke YD, et al. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6:e26860.
   PubMed Web of Science ®Google Scholar
• Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8:e72301.
   PubMed Web of Science ®Google Scholar
• Rajamohamedsait H, Rasool S, Rajamohamedsait W, et al. Prophylactic active tau immunization leads to sustained reduction in both tau and amyloid-beta pathologies in 3xTg mice. Sci Rep. 2017;7:17034.
   PubMed Web of Science ®Google Scholar
• Pedersen JT, Sigurdsson EM. Tau immunotherapy for Alzheimer’s disease. Trends Mol Med. 2015;21:394–402.
   PubMed Web of Science ®Google Scholar
• Coman H, Nemeş B. New therapeutic targets in Alzheimer’s disease. Int J Gerontol Internet. 2017;11:2–6. Available from: http://www.sciencedirect.com/science/article/pii/S1873959817300224
   Web of Science ®Google Scholar
• Makrides V, Shen TE, Bhatia R, et al. Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J Biol Chem. 2003;278:33298–33304.
   PubMed Web of Science ®Google Scholar
• Crowe A, Huang W, Ballatore C, et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry. 2009;48:7732–7745.
   PubMed Web of Science ®Google Scholar
• Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Heal & Aging. 2009;13:367–369.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A. 1996;93:11213–11218.
   PubMed Web of Science ®Google Scholar
• Necula M, Breydo L, Milton S, et al. Methylene blue inhibits amyloid abeta oligomerization by promoting fibrillization. Biochemistry. 2007;46:8850–8860.
   PubMed Web of Science ®Google Scholar
• Contestabile A. The history of the cholinergic hypothesis. Behav Brain Res. 2011;221:334–340.
   PubMed Web of Science ®Google Scholar
• Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet England. 1976;308(8000):1403.
   Google Scholar
• Bowen DM, Smith CB, White P, et al. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99:459–496.
   PubMed Web of Science ®Google Scholar
• Kar S, Issa AM, Seto D, et al. Amyloid beta-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J Neurochem. 1998;70:2179–2187.
   PubMed Web of Science ®Google Scholar
• Auld DS, Kar S, Quirion R. Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 1998;21:43–49.
   PubMed Web of Science ®Google Scholar
• Nordberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res. 1992;31:103–111.
   PubMed Web of Science ®Google Scholar
• Barage SH, Sonawane KD. Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1–18.
   PubMed Web of Science ®Google Scholar
• Franklin MC, Rudolph MJ, Ginter C, et al. Structures of paraoxon-inhibited human acetylcholinesterase reveal perturbations of the acyl loop and the dimer interface. Proteins. 2016;84:1246–1256.
   PubMed Web of Science ®Google Scholar
• Lleo A, Greenberg SM, Growdon JH. Current pharmacotherapy for Alzheimer’s disease. Annu Rev Med. 2006;57:513–533.
   PubMed Web of Science ®Google Scholar
• Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137–152.
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119–1122.
   PubMed Web of Science ®Google Scholar
• Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the american academy of neurology. Neurology. 2001;56:1154–1166.
   PubMed Web of Science ®Google Scholar
• Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer’s disease. Neurochem Res. 2003;28:515–522.
   PubMed Web of Science ®Google Scholar
• Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease. J Neural Transm Suppl. 2002;62:181–187.
   PubMedGoogle Scholar
• Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group Neurology. 1998;50:136–145.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol. 1998;1:55–65.
   Google Scholar
• Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The galantamine USA-10 study group. Neurology. 2000;54:2269–2276.
   PubMed Web of Science ®Google Scholar
• Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000;157:4–15.
   PubMed Web of Science ®Google Scholar
• Ryan J, Scali J, Carriere I, et al. Hormonal treatment, mild cognitive impairment and Alzheimer’s disease. Int Psychogeriatr Internet. 2008;20:47–56. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662345/
   PubMed Web of Science ®Google Scholar
• Gauthier S, Juby A, Dalziel W, et al. Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE). Curr Med Res Opin. 2010;26:1149–1160.
   PubMed Web of Science ®Google Scholar
• Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer’s disease: systematic review of the “real-world” evidence. Dement Geriatr Cogn Disord. 2009;28:389–403.
   PubMed Web of Science ®Google Scholar
• Giacobini E. Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann N Y Acad Sci. 2000;920:321–327.
   PubMed Web of Science ®Google Scholar
• Crismon ML. Tacrine: first drug approved for Alzheimer’s disease. Ann Pharmacother. 1994;28:744–751.
   PubMed Web of Science ®Google Scholar
• Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer’s disease. Int J Alzheimer’s Dis. 2012;2012:728983.
   Google Scholar
• Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3:303.
   PubMedGoogle Scholar
• Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;6:CD001190.
   Google Scholar
• Lopez-Arrieta JM, Schneider L. Metrifonate for Alzheimer’s disease. Cochrane Database Syst Rev. 2006;2:CD003155.
   PubMedGoogle Scholar
• Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A. 2005;102:17213–17218.
   PubMed Web of Science ®Google Scholar
• Leon R, Garcia AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer’s disease. Med Res Rev. 2013;33:139–189.
   PubMed Web of Science ®Google Scholar
• Geula C, Darvesh S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer’s disease. Drugs Today (Barc). 2004;40:711–721.
   PubMed Web of Science ®Google Scholar
• Wischik CM, Bentham P, Wischik DJ, et al. O3-04-07: tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer’s disease over 50 weeks. Alzheimer’s Dement J Alzheimer’s Assoc Internet. 2018;4:T167.
   Google Scholar
• Gura T. Hope in Alzheimer’s fight emerges from unexpected places. Nat Med U S. 2008;14:894.
   PubMed Web of Science ®Google Scholar
• Oz M, Lorke DE, Petroianu GA. Methylene blue and Alzheimer’s disease. Biochem Pharmacol. 2009;78:927–932.
   PubMed Web of Science ®Google Scholar
• Wagner SJ, Skripchenko A, Robinette D, et al. Factors affecting virus photoinactivation by a series of phenothiazine dyes. Photochem Photobiol. 1998;67:343–349.
   PubMed Web of Science ®Google Scholar
• Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. BrJ Pharmacol Internet. 2007;152:946–951. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2078225/
   PubMed Web of Science ®Google Scholar
• Clifton J 2nd, Leikin JB. Methylene blue. Am J Ther. 2003;10:289–291.
   PubMedGoogle Scholar
• Oz M, Isaev D, Lorke DE, et al. Methylene blue inhibits function of the 5-HT transporter. Br J Pharmacol. 2012;166:168–176.
   PubMed Web of Science ®Google Scholar
• de-Oliveira RW, Guimarães FS. Anxiolytic effect of methylene blue microinjected into the dorsal periaqueductal gray matter. Brazilian J Med Biol Res Scielo. 1999;32:1529–1532.
   PubMed Web of Science ®Google Scholar
• Rengelshausen J, Burhenne J, Frohlich M, et al. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol. 2004;60:709–715.
   PubMed Web of Science ®Google Scholar
• Peter C, Hongwan D, Kupfer A, et al. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol. 2000;56:247–250.
   PubMed Web of Science ®Google Scholar
• Lindahl PE, Öberg KE. The effect of rotenone on respiration and its point of attack. Exp Cell Res Internet. 1961;23:228–237. Available from: http://www.sciencedirect.com/science/article/pii/0014482761900337
   PubMed Web of Science ®Google Scholar
• Martinez JL, Jensen RA, Vasquez BJ, et al. Methylene blue alters retention of inhibitory avoidance responses. Physiol Psychol Internet. 1978;6:387–390.
   Google Scholar
• Callaway NL, Riha PD, Bruchey AK, et al. Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav. 2004;77:175–181.
   PubMed Web of Science ®Google Scholar
• Hauptmann S, Scherping I, Drose S, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2009;30:1574–1586.
   PubMed Web of Science ®Google Scholar
• Medina DX, Caccamo A, Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011;21:140–149.
   PubMed Web of Science ®Google Scholar
• Mayer B, Brunner F, Schmidt K. Novel actions of methylene blue. Eur Heart J. 1993;14(Suppl I):22–26.
   PubMedGoogle Scholar
• Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J Off Publ Fed Am Soc Exp Biol. 2008;22:703–712.
   PubMed Web of Science ®Google Scholar
• Oz M, Lorke DE, Hasan M, et al. Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev. 2011;31:93–117.
   PubMed Web of Science ®Google Scholar
• Schirmer RH, Adler H, Pickhardt M, et al. Lest we forget you – methylene blue …. Neurobiol Aging Internet. 2011;32:2325.e7–2325.e16. Available from: http://www.sciencedirect.com/science/article/pii/S0197458010005294
   PubMed Web of Science ®Google Scholar
• Kristiansen JE. Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. Dan Med Bull. 1989;36:178–185.
   PubMedGoogle Scholar
• Riha PD, Bruchey AK, Echevarria DJ, et al. Memory facilitation by methylene blue: dose-dependent effect on behavior and brain oxygen consumption. Eur J Pharmacol. 2005;511:151–158.
   PubMed Web of Science ®Google Scholar
• van der Ven AT, Pape JC, Hermann D, et al. Methylene blue (tetramethylthionine chloride) influences the mobility of adult neural stem cells: a potentially novel therapeutic mechanism of a therapeutic approach in the treatment of Alzheimer’s disease. J Alzheimers Dis. 2017;57:531–540.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lima F, Bruchey AK. Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem. 2004;11:633–640.
   PubMed Web of Science ®Google Scholar
• Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50:249–252.
   PubMed Web of Science ®Google Scholar
• Kelner MJ, Bagnell R, Hale B, et al. Potential of methylene blue to block oxygen radical generation in reperfusion injury. Basic Life Sci. 1988;49:895–898.
   PubMedGoogle Scholar
• Salaris SC, Babbs CF, Voorhees WD 3rd. Methylene blue as an inhibitor of superoxide generation by xanthine oxidase. A potential new drug for the attenuation of ischemia/reperfusion injury. Biochem Pharmacol. 1991;42:499–506.
   PubMed Web of Science ®Google Scholar
• Muller T. Methylene blue supravital staining: an evaluation of its applicability to the mammalian brain and pineal gland. Histol Histopathol. 1998;13:1019–1026.
   PubMed Web of Science ®Google Scholar
• DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II. Methylene blue – absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. 1972;61:1086–1090.
   PubMed Web of Science ®Google Scholar
• Lorke DE, Kalasz H, Petroianu GA, et al. Entry of oximes into the brain: a review. Curr Med Chem. 2008;15:743–753.
   PubMed Web of Science ®Google Scholar
• Herman MI, Chyka PA, Butler AY, et al. Methylene blue by intraosseous infusion for methemoglobinemia. Ann Emerg Med. 1999;33:111–113.
   PubMed Web of Science ®Google Scholar
• Buchholz K, Schirmer RH, Eubel JK, et al. Interactions of methylene blue with human disulfide reductases and their orthologues from plasmodium falciparum. Antimicrob Agents Chemother. 2008;52:183–191.
   PubMed Web of Science ®Google Scholar
• Bongard RD, Krenz GS, Linehan JH, et al. Reduction and accumulation of methylene blue by the lung. J Appl Physiol. 1994;77:1480–1491.
   PubMed Web of Science ®Google Scholar
• Harris JE, Peters A. Experiments on vital staining with methylene blue. Q J Microsc Sci Internet. 1953;3(26):113–124. Available from: http://jcs.biologists.org/content/s3-94/26/113.abstract
   Google Scholar
• Taniguchi S, Suzuki N, Masuda M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem. 2005;280:7614–7623.
   PubMed Web of Science ®Google Scholar
• Necula M, Kayed R, Milton S, et al. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem. 2007;282:10311–10324.
   PubMed Web of Science ®Google Scholar
• Dolphin GT, Chierici S, Ouberai M, et al. A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer’s beta-amyloid fibril formation. Chembiochem. 2008;9:952–963.
   PubMed Web of Science ®Google Scholar
• Fischer R, Zeman W. Neuronal dye-sorption as a histochemical indicator of nervous activity. Nature Internet]. 1959;183:1337.
   PubMed Web of Science ®Google Scholar
• Holzgrabe U, Kapkova P, Alptuzun V, et al. Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets. 2007;11:161–179.
   PubMed Web of Science ®Google Scholar
• Nordberg A. Mechanisms behind the neuroprotective actions of cholinesterase inhibitors in Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S12–8.
   PubMed Web of Science ®Google Scholar
• Pfaffendorf M, Bruning TA, Batnik HD, et al. The interaction between methylene blue and the cholinergic system. Br J Pharmacol. 1997;122:95–98.
   PubMed Web of Science ®Google Scholar
• Kucukkilinc T, Ozer I. Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes. Arch Biochem Biophys. 2007;461:294–298.
   PubMed Web of Science ®Google Scholar
• Yucel YY, Tacal O, Ozer I. Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008;478:201–205.
   PubMed Web of Science ®Google Scholar
• Inestrosa NC, Dinamarca MC, Alvarez A. Amyloid-cholinesterase interactions. Implications for Alzheimer’s disease. FEBS J. 2008;275:625–632.
   PubMed Web of Science ®Google Scholar
• Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap. 2011;155:219–223.
   PubMed Web of Science ®Google Scholar
• Fujii T, Mori Y, Tominaga T, et al. Maintenance of constant blood acetylcholine content before and after feeding in young chimpanzees. Neurosci Lett. 1997;227:21–24.
   PubMed Web of Science ®Google Scholar
• Joachim H, Cornelia K, DE G, et al. Excessive hippocampal acetylcholine levels in acetylcholinesterase‐deficient mice are moderated by butyrylcholinesterase activity. J Neurochem Internet. 2006;100:1421–1429.
   PubMed Web of Science ®Google Scholar
• Guevara-Salazar JA, Espinoza-Fonseca M, Beltrán HI, et al. The electronic influence on the active site-directed inhibition of acetylcholinesterase by N-aryl-substituted succinimides. J Mex Chem Soc. 2007;51:222–227.
   Web of Science ®Google Scholar
• Jońca J, Żuk M, Wasąg B, et al. New insights into butyrylcholinesterase activity assay: serum dilution factor as a crucial parameter. PLoS One. 2015;10:e0139480.
   PubMed Web of Science ®Google Scholar
• Lockridge O, Norgren RB Jr, Johnson RC, et al. Naturally occurring genetic variants of human acetylcholinesterase and butyrylcholinesterase and their potential impact on the risk of toxicity from cholinesterase inhibitors. Chem Res Toxicol. 2016;29:1381–1392.
   PubMed Web of Science ®Google Scholar
• Masson P, Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch Biochem Biophys. 2010;494:107–120.
   PubMed Web of Science ®Google Scholar
• Bono GF, Simão-Silva DP, Batistela MS, et al. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer’s disease in a Southern Brazilian population. Neurochem Int. 2015;81:57–62.
   PubMed Web of Science ®Google Scholar
• Brunton LL, Chabner BA, Knollmann BC. As Bases Farmacológicas da Terapêutica de Goodman & Gilman-12.ed. McGraw Hill Brasil. 2012; 2112 p.
   Google Scholar
• Silman I, Sussman JL. Acetylcholinesterase: ‘classical’and ‘non-classical’ functions and pharmacology. Curr Opin Pharmacol. 2005;5:293–302.
   PubMed Web of Science ®Google Scholar
• Koelle GB. Pharmacology of organophosphates. J Appl Toxicol. 1994;14:105–109.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Nadel A, Masterman D, et al. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol. 2001;14:101–108.
   PubMed Web of Science ®Google Scholar
• Blass JP, Cyrus PA, Bieber F, et al. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The metrifonate study group. Alzheimer Dis Assoc Disord. 2000;14:39–45.
   PubMed Web of Science ®Google Scholar
• Heinig R, Sachse R. The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate. Int J Clin Pharmacol Ther. 1999;37:456–464.
   PubMed Web of Science ®Google Scholar
• Pohanka M, Novotny L, Pikula J. Metrifonate alters antioxidant levels and caspase activity in cerebral cortex of wistar rats. Toxicol Mech Methods. 2011;21:585–590.
   PubMed Web of Science ®Google Scholar
• Kronforst-Collins MA, Moriearty PL, Ralph M, et al. Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits. Pharmacol Biochem Behav. 1997;56:103–110.
   PubMed Web of Science ®Google Scholar
• Kronforst-Collins MA, Moriearty PL, Schmidt B, et al. Metrifonate improves associative learning and retention in aging rabbits. Behav Neurosci. 1997;111:1031–1040.
   PubMed Web of Science ®Google Scholar
• Abdi A, Sadraie H, Dargahi L, et al. Apoptosis inhibition can be threatening in a beta-induced neuroinflammation, through promoting cell proliferation. Neurochem Res. 2011;36:39–48.
   PubMed Web of Science ®Google Scholar
• Mori F, Lai CC, Fusi F, et al. Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport. 1995;6:633–636.
   PubMed Web of Science ®Google Scholar
• Lamb HM, Faulds D. Metrifonate. Drugs Aging Internet. 1997;11:490–496. .
   PubMed Web of Science ®Google Scholar
• Ansari N, Khodagholi F. Natural products as promising drug candidates for the treatment of Alzheimer’s disease: molecular mechanism aspect. Curr Neuropharmacol. 2013;11:414–429.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75:311–335.
   PubMed Web of Science ®Google Scholar
• Asadi S, Ahmadiani A, Esmaeili MA, et al. In vitro antioxidant activities and an investigation of neuroprotection by six Salvia species from Iran: a comparative study. Food Chem Toxicol. 2010;48:1341–1349.
   PubMed Web of Science ®Google Scholar
• Kuruuzum-Uz A, Suleyman H, Cadirci E, et al. Investigation on anti-inflammatory and antiulcer activities of anchusa azurea extracts and their major constituent rosmarinic acid. Z Naturforsch C. 2012;67:360–366.
   PubMed Web of Science ®Google Scholar
• Jimenez-Aliaga K, Bermejo-Bescos P, Benedi J, et al. Quercetin and rutin exhibit antiamyloidogenic and fibril-disaggregating effects in vitro and potent antioxidant activity in APPswe cells. Life Sci. 2011;89:939–945.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Abdul HM, Joshi G, et al. Protective effect of quercetin in primary neurons against Abeta(1–42): relevance to Alzheimer’s disease. J Nutr Biochem. 2009;20:269–275.
   PubMed Web of Science ®Google Scholar
• Li F, Gong Q, Dong H, et al. Resveratrol, a neuroprotective supplement for Alzheimer’s disease. Curr Pharm Des. 2012;18:27–33.
   PubMed Web of Science ®Google Scholar
• Ge J-F, Qiao J-P, Qi -C-C, et al. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int. 2012;61:1192–1201.
   PubMed Web of Science ®Google Scholar
• Luo L, Huang Y. [Effect of resveratrol on the cognitive ability of Alzheimeros mice]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2006;31:566–569.
   PubMedGoogle Scholar
• Zhou F, Chen S, Xiong J, et al. Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells. Biol Trace Elem Res. 2012;149:273–279.
   PubMed Web of Science ®Google Scholar
• Liu R, Meng F, Zhang L, et al. Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevents copper-mediated toxicity in beta-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells. Molecules. 2011;16:2084–2096.
   PubMed Web of Science ®Google Scholar
• Vuddanda PR, Chakraborty S, Singh S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin Investig Drugs. 2010;19:1297–1307.
   PubMed Web of Science ®Google Scholar
• Wu T-Y, Chen C-P, Jinn T-R. Traditional Chinese medicines and Alzheimer’s disease. Taiwan J Obstet Gynecol Internet. 2011;50:131–135. Available from: http://www.sciencedirect.com/science/article/pii/S102845591100101X
   PubMed Web of Science ®Google Scholar
• Pohl F, Kong Thoo Lin P. The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials. Molecules. 2018;23(12):23.
   Web of Science ®Google Scholar
• Shen Y-M, Chen D-Z. An explorer of chemical biology of plant natural products in Southwest China, Xiaojiang Hao. Nat Products Bioprospect. 2018;8:217–226.
   PubMed Web of Science ®Google Scholar
• Ivanova L, Karelson M, Dobchev DA. Identification of natural compounds against neurodegenerative diseases using in silico techniques. Molecules. 2018;23:1847.
   Web of Science ®Google Scholar
• Tzvetkov NT, Atanasov AG. Natural product-based multitargeted ligands for Alzheimer’s disease treatment?. Future Med Chem. 2018;10:1745–1748.
   PubMed Web of Science ®Google Scholar
• Shal B, Ding W, Ali H, et al. Anti-neuroinflammatory potential of natural products in attenuation of Alzheimer’s disease. Front Pharmacol. 2018;9:548.
   PubMed Web of Science ®Google Scholar
• Yi L, Liu W, Wang Z, et al. Characterizing Alzheimer’s disease through metabolomics and investigating anti-Alzheimer’s disease effects of natural products. Ann N Y Acad Sci. 2017;1398:130–141.
   PubMed Web of Science ®Google Scholar
• Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model & Mech. 2017;10(499):LP–502.
   Google Scholar
• Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14:111–129.
   PubMed Web of Science ®Google Scholar
• Wang S, Wang D, Liu Z. Synergistic, additive and antagonistic effects of potentilla fruticosa combined with EGb761 on antioxidant capacities and the possible mechanism. Ind Crops Prod. 2015;67:227–238.
   Web of Science ®Google Scholar
• Skroza D, Generalić Mekinić I, Svilović S, et al. Investigation of the potential synergistic effect of resveratrol with other phenolic compounds: a case of binary phenolic mixtures. J Food Compos Anal. 2015;38:13–18.
   Web of Science ®Google Scholar
• Sabogal-Guaqueta AM, Munoz-Manco JI, Ramirez-Pineda JR, et al. The flavonoid quercetin ameliorates Alzheimer’s disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer’s disease model mice. Neuropharmacology. 2015;93:134–145.
   PubMed Web of Science ®Google Scholar
• Ma T, Tan M-S, Yu J-T, et al. Resveratrol as a therapeutic agent for Alzheimer’s disease. Biomed Res Int [Internet]. 2014/11/26. 2014;2014:350516. Available from: https://www.ncbi.nlm.nih.gov/pubmed/25525597
   PubMedGoogle Scholar
• Ahmed T, Javed S, Javed S, et al. Resveratrol and Alzheimer’s disease: mechanistic insights. Mol Neurobiol. 2017;54:2622–2635.
   PubMed Web of Science ®Google Scholar
• Kou X, Chen N. Resveratrol as a natural autophagy regulator for prevention and treatment of Alzheimer’s disease. Nutrients Internet. 2017;9:927. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28837083
   PubMed Web of Science ®Google Scholar
• Ji H-F, Shen L. Berberine: a potential multipotent natural product to combat Alzheimer’s disease. Molecules. 2011;16:6732–6740.
   PubMed Web of Science ®Google Scholar
• Cai Z, Wang C, Yang W. Role of berberine in Alzheimer’s disease. Neuropsychiatr Dis Treat Internet. 2016;12:2509–2520. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27757035
   PubMed Web of Science ®Google Scholar
• Potschka H. Targeting the brain–surmounting or bypassing the blood-brain barrier. Handb Exp Pharmacol. 2010;197:411–431.
   PubMedGoogle Scholar
• Silva GA. Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system. Ann N Y Acad Sci. 2010;1199:221–230.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65–81.
   PubMed Web of Science ®Google Scholar
• Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;7:521–540.
   PubMed Web of Science ®Google Scholar
• Kostarelos K, Miller AD. Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem Soc Rev Internet. 2005;34:970–994.
   PubMed Web of Science ®Google Scholar
• Borm PJA, Muller-Schulte D. Nanoparticles in drug delivery and environmental exposure: same size, same risks? Nanomedicine (Lond). 2006;1:235–249.
   PubMed Web of Science ®Google Scholar
• Xu ZP, Zeng QH, Lu GQ, et al. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci Internet. 2006;61:1027–1040. Available from: http://www.sciencedirect.com/science/article/pii/S0009250905005609
   Web of Science ®Google Scholar
• Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv. 2008;5:105–117.
   PubMed Web of Science ®Google Scholar
• Leary SP, Liu CY, Apuzzo MLJ. Toward the emergence of nanoneurosurgery: part III – nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. Neurosurgery. 2006;58:1009–1026.
   PubMed Web of Science ®Google Scholar
• Modi G, Pillay V, Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci. 2010;1184:154–172.
   PubMed Web of Science ®Google Scholar
• Jain KK. Role of nanotechnology in developing new therapies for diseases of the nervous system. Nanomedicine (Lond) England. 2006;1:9–12.
   PubMed Web of Science ®Google Scholar
• Silva GA. Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci. 2006;7:65–74.
   PubMed Web of Science ®Google Scholar
• Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis. 2008;13:199–223.
   PubMed Web of Science ®Google Scholar
• Mortimer JA, Borenstein AR, Gosche KM, et al. Very early detection of alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol Internet. 2005;18:218–223. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1405917/
   PubMed Web of Science ®Google Scholar
• Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer’s disease. Nat Med. 2004;10(Suppl):S34–41.
   PubMedGoogle Scholar
• Teunissen CE, de Vente J, Steinbusch HWM, et al. Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002;23:485–508.
   PubMed Web of Science ®Google Scholar
• Nazem A, Mansoori GA. Nanotechnology for Alzheimer’s disease detection and treatment. Insciences. 2011;1:169–193.
   Google Scholar
• Ikeda K, Okada T, Sawada S-I, et al. Inhibition of the formation of amyloid beta-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS Lett. 2006;580:6587–6595.
   PubMed Web of Science ®Google Scholar
• Boridy S, Takahashi H, Akiyoshi K, et al. The binding of pullulan modified cholesteryl nanogels to Abeta oligomers and their suppression of cytotoxicity. Biomaterials Internet. 2009;30:5583–5591. Available from: http://europepmc.org/abstract/MED/19577802
   PubMed Web of Science ®Google Scholar
• Dugan LL, Lovett EG, Quick KL, et al. Fullerene-based antioxidants and neurodegenerative disorders. Parkinsonism Relat Disord. 2001;7:243–246.
   PubMed Web of Science ®Google Scholar
• Jain KK. The role of nanobiotechnology in drug discovery. Drug Discov Today. 2005;10:1435–1442.
   PubMed Web of Science ®Google Scholar
• Podolski IY, Podlubnaya ZA, Kosenko EA, et al. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J Nanosci Nanotechnol. 2007;7:1479–1485.
   PubMed Web of Science ®Google Scholar
• Dugan LL, Gabrielsen JK, Yu SP, et al. Buckminsterfullerenol free radical scavengers reduce excitotoxic and apoptotic death of cultured cortical neurons. Neurobiol Dis. 1996;3:129–135.
   PubMed Web of Science ®Google Scholar
• Nikakhtar A, Nasehzadeh A, Mansoori GA. Formation and stability conditions of DNA-dendrimer nano-clusters. J Comput Theor Nanosci. 2007;4:521–528.
   Google Scholar
• Klajnert B, Cortijo-Arellano M, Cladera J, et al. Influence of dendrimer’s structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun. 2006;345:21–28.
   PubMed Web of Science ®Google Scholar
• Kogan MJ, Bastus NG, Amigo R, et al. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 2006;6:110–115.
   PubMed Web of Science ®Google Scholar
• Rawat M, Singh D, Saraf PS. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull. 2006;29:1790–1798.
   PubMed Web of Science ®Google Scholar
• Wang J, Valmikinathan CM, Yu X. Nanostructures for bypassing blood brain barrier [Internet]. Curr Bioact Compd. 2009;5(3):195–205. Available from: http://www.eurekaselect.com/node/69894/article
   Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, et al. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59:454–477.
   PubMed Web of Science ®Google Scholar
• Bush AI. Drug development based on the metals hypothesis of Alzheimer’s disease. J Alzheimers Dis. 2008;15:223–240.
   PubMed Web of Science ®Google Scholar
• Curtain CC, Ali F, Volitakis I, et al. Alzheimer’s disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem. 2001;276:20466–20473.
   PubMed Web of Science ®Google Scholar
• Goncalves AS, Costa FTC, Caetano MS, et al. Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: reducing the computational cost in hybrid QM/MM methods. J Biom Struct& Dyn. 2014;32:301–307.
   PubMed Web of Science ®Google Scholar
• Ramalho TC, de Castro AA, Tavares TS, et al. Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: current status and future expectations. Prog Neurobiol. 2018;169:135–157.
   PubMed Web of Science ®Google Scholar
• De O Freitas LB, Borgati TF, De Freitas RP, et al. Synthesis and antiproliferative activity of 8-hydroxyquinoline derivatives containing a 1,2,3-triazole moiety. Eur J Med Chem. 2014;84:595–604.
   Google Scholar